Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. As a result, Sponsors and CROs can benefit from simplified access to international clinical research capabilities. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

ACRP blog

JANUARY 24, 2023

Raising Community Awareness to Optimize Impact Nevada’s first integrated health system was created in June 2021 when an affiliation agreement was signed between Renown Health and the University of Nevada, Reno, School of Medicine. An important step was a review of the state of clinical trial awareness at the time of the affiliation agreement.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2021

In the FIGARO-DKD study, presented at ESC Congress 2021 and published in the New England Journal of Medicine, the prevalence of the first secondary endpoint, a compound of time to order failure, a sustained drop of estimated glomerular filtration rate (eGFR) ? cases in the finerenone arm and 395 (10.8)

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Scienmag

MAY 16, 2021

A unique commission that today issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women was led by Roxana Mehran, MD, Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine (..)

Clinical Trials 50

Clinical Trials Clinical Trials Medicine Trials 50

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

Clinical Trials 92

Clinical Trials Clinical Trials Life Science Clinical Research 92

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. The vericiguat program is being co-developed by Bayer and MSD.

Cardiology 52

Cardiology Production Development Medicine 52

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of Senior Vice President, Clinical Development, BlueRock Therapeutics.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

Scienmag

JANUARY 11, 2021

COVID-19 pneumonia spreads like multiple wildfires, leaving destroyed lung tissue in its wake ‘This effort truly represents a “moonshot” in COVID-19 research’ Scientists identify target to treat COVID pneumonia and reduce severity Clinical trials with new experimental drug to begin early in 2021 Goal is to develop treatments (..)

Clinical Trials 49

Clinical Trials Clinical Trials Scientist Trials 49

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

Clinical Trials 52

Clinical Trials Clinical Trials Life Science Clinical Research 52

Scienmag

JUNE 17, 2021

Tools for clinicians in point-of-care use UTICA, NY — More than 2 million coronary artery stents are implanted each year to help protect or restore normal blood flow to the heart, to treat patients suffering from angina or a heart attack due to coronary artery disease (CAD). While stents are highly effective and safe devices, […].

Research 72

Research Development Clinical Trials Clinical Trials 72

The Pharma Data

JANUARY 20, 2021

In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the trial. The CEC comprises clinical experts in cardiology and Intensive Care and has been established to ensure accurate and consistent assessment of the trial endpoints and/or serious adverse events.

Trials 52

Trials Cardiology Containment Development 52

The Pharma Data

MARCH 31, 2023

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. The trial was conducted in 30 countries and 105 clinical sites across North America, Europe, Asia and Latin America 3. About our longstanding commitment to heart failure Our goal is to reimagine medicine for HF patients.

Medicine 75

Medicine Trials Cardiology Production 75

The Pharma Data

AUGUST 22, 2021

Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). The IDMC recommended that the trial be discontinued due to lack of efficacy.

Trials 52

Trials Clinical Trials Clinical Trials Cardiology 52

The Pharma Data

SEPTEMBER 5, 2021

The approval by the European Commission was based on interim results from the Phase III clinical trial in children and adolescents with PNH that demonstrated the safety and efficacy of Ultomiris in these patients. Ultomiris is administered every four or eight weeks (depending on body weight), following a loading dose.

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

The Pharma Data

AUGUST 30, 2021

ALXN1840, a potential new once-daily, oral medicine, demonstrated approximately three times greater copper mobilisation than SoC. The trial enrolled 214 patients, including treatment-naïve participants and those who have been on SoC therapy for an average of ten or more years. 1 It affects one in 30,000 live births in the US.

Trials 52

Trials Genetics Cardiology Medicine 52

The Pharma Data

JULY 12, 2021

Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and principal investigator of the FIDELIO-DKD trial. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. The study met its primary endpoint.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

DECEMBER 15, 2020

And you won’t be spared simply by keeping high blood pressure at bay until you hit your golden years, because the study found that even those who hadn’t developed high blood pressure until becoming seniors still experienced a faster decline in thinking skills than those who continued to remain heart-healthy in their golden years.

Cardiology 52

Cardiology Clinical Trials Clinical Trials Medicine 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis. Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. CAEL-101 has received Orphan Drug Designation from both the U.S. About AL Amyloidosis.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

WCG Clinical

MAY 22, 2023

Despite the growing consensus around the need for diversity in clinical trials, the industry still has a long way to go. 4,5 In fact, lack of representation in clinical trials compromises generalizability of research findings. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Cardiology 52

The Pharma Data

AUGUST 30, 2021

The findings from the FIGARO-DKD study were presented today during a Hot Line session at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. Despite current treatment options, patients remain at high risk of progression to kidney failure and cardiovascular events,” said Professor Gerasimos Filippatos, M.D.,

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 2, 2020

Bronchitol was developed by Pharmaxis Ltd., market and congratulate all Chiesi team members and partners who supported the clinical process.”. In three large-scale global clinical trials totaling 761 patients aged 18 years and older, Bronchitol use led to a sustained improvement in FEV 1 (Forced Expiratory Volume) versus control.

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

Pharma Marketing Network

JANUARY 12, 2023

Advancing medicine, advancing patient care, and advancing equity in our global workforce are shared values of this year’s honorees driving transformational change and impact,” said Wendy White, interim CEO and 2022 STAR, HBA. These experiences have empowered Christi to become a leading industry voice advocating fiercely for patients.

Life Science 52

Life Science Manufacturing Cardiology Development 52

Scienmag

APRIL 27, 2021

Researchers from Belgium, the Netherlands, Russia, and Italy have developed a breakthrough method for quickly, accurately, and reliably diagnosing cardiac arrhythmias. The technology principles are published in JACC: Clinical […]. This is a unique method to diagnose pathogenic areas in the heart in a minute Credit: Front.

Scientist 96

Scientist Development Research Clinical Trials 96

Rethinking Clinical Trials

APRIL 13, 2023

Nudges and other behavioral interventions are prevalent in industries like business and entertainment, but there is an opportunity for nudges in medicine and health care delivery. Launched in 2016, the Penn Medicine Nudge Unit is the world’s first behavioral design team embedded within a health system.

Medicine 100

Medicine Trials Cardiology Development 100

Scienmag

OCTOBER 8, 2020

. – A medical-device startup that aims to improve the health of pregnant women is the top winner in an annual pitch contest presented by the Massachusetts Medical Device Development Center (M2D2). Now in its ninth year, the M2D2 $200K Challenge showcases the inventions […].

Development 71

Development Clinical Trials Clinical Trials Cardiology 71

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

Scienmag

OCTOBER 6, 2020

Three ongoing influenza vaccine cardiovascular outcomes trials could hold insights into testing novel interventions against COVID-19 Seasonal influenza vaccine development and mass production, as well as three international influenza vaccine cardiovascular outcomes trials currently underway, may inform future efforts targeted at developing and evaluating (..)

Vaccination 40

Vaccination Vaccine Trials Production 40

The Pharma Data

MARCH 22, 2022

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb. “We

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

The Pharma Data

JANUARY 12, 2021

– Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 – – Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 12, 2021– Alexion Pharmaceuticals, Inc. “For

Containment 52

Containment Development Sales Production 52

The Pharma Data

NOVEMBER 4, 2020

ULTOMIRIS is a prescription medicine used to treat: adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. INDICATIONS & IMPORTANT SAFETY INFORMATION for ULTOMIRIS ® (ravulizumab-cwvz).

Doctors 52

Doctors Doctor Vaccination Vaccine 52